<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OPN-15006417</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-05-13</date_registration>
      <primary_sponsor>Department of Hematology, Peking Union Medical College Hospital</primary_sponsor>
      <public_title>High dose Methotrexate (MTX) followed by Etoposide, Cytarabine (EA), stem cell support and temozolomide maintenance therapy in patients with newly diagnosed Primary Central Nervous System B-cell Lymphoma</public_title>
      <acronym />
      <scientific_title>High dose Methotrexate (MTX) followed by Etoposide, Cytarabine (EA), stem cell support and temozolomide maintenance therapy in patients with newly diagnosed Primary Central Nervous System B-cell Lymphoma</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-06-01</date_enrolment>
      <type_enrolment />
      <target_size>Case series:30;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10959</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Post-market</phase>
      <hc_freetext>Primary Central Nervous System B-cell Lymphoma</hc_freetext>
      <i_freetext>Case series:High dose Methotrexate (MTX) followed by Etoposide, Cytarabine (EA), stem cell support and temozolomide maintenance therapy;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Wei Zhang</firstname>
        <middlename />
        <lastname />
        <address>1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13681473557</telephone>
        <email>vv1223@vip.sina.com</email>
        <affiliation>Department of Hematology, Peking Union Medical College Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Daobin Zhou</firstname>
        <middlename />
        <lastname />
        <address>1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13901113623</telephone>
        <email>daobinzhou@yahoo.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2 />
    </countries>
    <criteria>
      <inclusion_criteria>1. Diagnosis of Primary Central Nervous System B-cell Lymphoma;
2. Age:18-70;
3. Eastern Cooperative Oncology Group (ECOG) status 0-2 and no chemotherapy contraindications;
4. Estimated survival time &gt;3 months;
5. All patients have to sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Pregnant or lactating women;
2. Patients combined with any unstable systemic diseases;
3. Hypersensitiveness to any kind of trial regime;
4. Histopathological diagnosis of T cell lymphoma, or Lymphoma cells in bone marrow &gt;=25%.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Overall Response Rate;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Grade 3/4 toxicities;Time to progress;Overall survival rate;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self fund</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>